Lamar Advertising Q4 Earnings Call Highlights

Core Insights - Lamar Advertising reported strong performance in several categories, particularly services, healthcare, building and construction, and financial advertising, while telecom and beer and wine showed weakness [1] - The company experienced local revenue growth of 1.7% and national programmatic growth of 3.3%, marking the third consecutive quarter of national growth [2] - CEO Sean Reilly noted that both local and national advertising grew in Q4, with a strong finish to the year, citing December pro forma growth of almost 6% [3] Financial Performance - For Q4, diluted AFFO per share rose 1.4% to $2.24, adjusted EBITDA increased 3.7% to $288.9 million, and the adjusted EBITDA margin improved to 48.5% [9] - For the full year, acquisition-adjusted revenue increased 2.1% to $2.27 billion, while adjusted EBITDA totaled $1.06 billion, up 1.4% [11] - Management guided to 2026 AFFO of $8.50 to $8.70 per share, implying about 4.1% year-over-year growth [12] Acquisitions and Balance Sheet - Lamar completed 50 acquisitions in 2025 for $191 million and expects around $200 million in cash acquisitions in 2026 [5][13] - The company ended the year with total debt of approximately $3.4 billion and a leverage ratio of 2.92x [14] - Lamar has over $800 million in total liquidity, including cash and available credit [14] Digital Expansion - In Q4, Lamar added 111 digital units, ending the year with 5,553 digital displays, which represented 33.7% of Q4 business [6][8] - Same-store digital revenue increased 3.7% in Q4, reflecting continued advertiser demand for digital flexibility [8] Advertising Trends - Political advertising was a headwind in Q4, with expectations for a reversal in 2026, estimating an increase of $12 million to $14 million in political revenue [16] - The company anticipates additional advertising related to the World Cup, estimating $3 million to $4 million of incremental business [17] - Optimism around pharmaceutical advertising is noted, driven by changes in FDA disclosure requirements [18]